101,600
-1.55%
Close of 9 Nov 2026, in KRW
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Daewoong Pharma
Its shares trade on KRX under the ticker 069620.KS. It has been listed since 1 November 2002. In the fiscal year to 31 December 2025, it reported revenue of ₩1.57trn and net income of ₩195.86bn. At that date it held total assets of ₩2.36trn and shareholders' equity of ₩1.01trn.
Daewoong Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceuticals. The company is headquartered in Hwaseong, Gyeonggi-Do. The company went IPO on 2002-11-01. The firm's products mainly include antihypertensive drugs, antianemic agents, antidiabetic agents, antiemetic agents, antihistamine agents, antimicrobials, antineoplastics, antiobesity agents, antipyretic agents, analgesic agents, anti-inflammatory agents, biosimilars, remedies for bone and joint diseases, cardiovascular treatments, central nervous system treatments, digestive agents, dermatologic agents, gastrointestinal agents, health supplements and respiratory remedies, among others. The firm distributes its products in domestic and overseas markets.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 1 Nov 2002
- Website
- daewoong.co.kr ↗
Leadership
Pay as last reported
- Mr. Seung Ho JeonCo-President, Co-Chief Executive Officer, Director, since 2018₩600.0m
- Mr. Chang Jae LeeCo-President, Co-Chief Executive Officer, Director, since 2022
- Mr. Jae Chun YoonCo-President, Co-Chief Executive Officer, Director, since 2018
- Mr. Geon Haeng LeeInternal Auditor
- Mr. Dae Deok KimNon-Executive Independent Director
- Mr. Hong Cheol KimNon-Executive Independent Director
- Mr. Yeong Jin KimNon-Executive Independent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Daewoong Pharma has a strong research and development division, enabling them to develop innovative and high-quality pharmaceutical products.
- The company has a diverse portfolio of products in various therapeutic areas, providing a competitive advantage and reducing dependency on a single product or market.
- Daewoong Pharma has a well-established brand reputation both domestically and internationally, enhancing customer trust and attracting new business opportunities.
Weaknesses
- The company heavily relies on a limited number of key products for a significant portion of its revenue, making it vulnerable to market fluctuations or regulatory changes affecting these specific products.
- Daewoong Pharma faces intense competition, particularly in the global pharmaceutical market, which may limit its market share and profitability.
- There have been concerns raised about the company's corporate governance practices, which may impact investor confidence and potentially hamper growth prospects.
Opportunities
- Expanding into new geographic markets where there is potential for growth and demand for pharmaceutical products could be a fruitful opportunity for Daewoong Pharma.
- The increasing focus on healthcare and advancements in medical technology provide an opportunity for the company to develop and introduce innovative therapies and treatments.
- Strategic partnerships or acquisitions with smaller biotech firms or research organizations can offer Daewoong Pharma access to novel drug candidates or advanced technologies.
Threats
- The strict regulatory and approval processes in the pharmaceutical industry pose a threat to Daewoong Pharma's ability to successfully bring new products to market.
- The emergence of generic drugs or biosimilars could erode market share and profitability for Daewoong Pharma's existing products, particularly if they lose patent protection.
- Geopolitical or economic uncertainties, such as trade disputes or currency fluctuations, can impact the company's international operations and market expansion plans.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.